瑞舒伐他汀与阿托伐他汀治疗冠心病血脂疗效与安全性比较的Meta分析

被引：31

作者：

万埝

夏豪

刘小熊

梅阳

唐东梁

机构：

[1] 武汉大学人民医院心血管内科

来源：

疑难病杂志 | 2014年 / 13卷 / 04期

关键词：

瑞舒伐他汀; 阿托伐他汀; 冠状动脉粥样硬化性心脏病; Meta分析;

D O I：

暂无

中图分类号：

R541.4 [冠状动脉（粥样）硬化性心脏病（冠心病）];

学科分类号：

1002 ; 100201 ;

摘要：

目的系统性评价瑞舒伐他汀(RSV)与阿托伐他汀(ATV)治疗冠状动脉粥样硬化性心脏病血脂的疗效与安全性。方法计算机检索PUBMED、VIP、中国知网、万方数据库关于RSV与ATV治疗冠心病的疗效与安全性的随机对照试验(RCT),同时追索纳入文献的参考文献。检索时限为2003—2013年。根据Jadad评分对纳入文献的质量进行严格评价和资料提取,对符合质量标准的RCT进行Meta分析。统计学分析采用RevMan5.0.25软件。结果共纳入10项RCT。Meta分析结果显示:(1)LDL—C变化:RSV与ATV相比,差异无统计学意义(MD=-3.99,95%CI-9.34～1.37,P>0.05);(2)HDL-C变化:RSV与ATV相比,差异有统计学意义(MD=1.80,95%CI 1.74～1.86,P<0.01);(3)TG变化:RSV与ATV相比,差异无统计学意义(MD=9.31,95%CI-3.74～22.37,P>0.05);(4)TC变化:RSV与ATV相比,差异无统计学意义(MD=-1.21,95%CI—12.39～9.95,P>0.05);(5)不良事件(AE)发生率:RSV与ATV相比,差异无统计学意义(OR=1.02,95%CI 0.80～1.29,P>0.05)。结论与阿托伐他汀相比,瑞舒伐他汀在改善冠心病患者LDL-C、TG、TC的疗效和AE发生率方面无优越性。

引用

页码：403 / 407

页数：5

共 18 条

[11] Effects of Rosuvastatin versus Atorvastatin on Rho-associated Coiled-coil Containing Protein Kinase Activity and Endothelial Function in Patients with Atherosclerosis [J].

Liu, B. ;

Cao, H. M. ;

Li, G. Y. ;

Liu, M. ;

Feng, J. ;

Li, J. ;

Wang, Q. .

JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2011, 39 (06) :2314-2322

[12] A systematic review and meta-analysis on the therapeutic equivalence of statins [J].

Weng, T. -C. ;

Yang, Y. -H. Kao ;

Lin, S. -J. ;

Tai, S. -H. .

JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2010, 35 (02) :139-151

[13] Comparison of Effects of Rosuvastatin (10 mg) Versus Atorvastatin (40 mg) on Rho Kinase Activity in Caucasian Men With a Previous Atherosclerotic Event [J].

Rawlings, Ron ;

Nohria, Anju ;

Liu, Ping-Yen ;

Donnelly, Jason ;

Creager, Mark A. ;

Ganz, Peter ;

Selwyn, Andrew ;

Liao, James K. .

AMERICAN JOURNAL OF CARDIOLOGY, 2009, 103 (04) :437-441

[14]

Statin Therapy Alters the Relationship Between Apolipoprotein B and Low-Density Lipoprotein Cholesterol and Non–High-Density Lipoprotein Cholesterol Targets in High-Risk Patients[J] . Christie M. Ballantyne,Joel S. Raichlen,Valerie A. Cain.Journal of the American College of Cardiology . 2008 (8)

[15] Comparison of rosuvastatin versus atorvastatin in South-Asian patients at risk of coronary heart disease (from the IRIS trial) [J].

Deedwania, Prakash C. ;

Gupta, Milan ;

Stein, Michael ;

Ycas, Joseph ;

Gold, Alex .

AMERICAN JOURNAL OF CARDIOLOGY, 2007, 99 (11) :1538-1543

[16]

Twelve-week, multicenter, randomized, open-label comparisonof the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study[J] . Timo E. Strandberg,John Feely,Emil L. Sigurdsson.Clinical Therapeutics . 2004 (11)

[17]

Efficacy and safety of rosuvastatin and atorvastatin in patients with hypercholesterolemia and a high risk of coronary heart disease: a randomized, controlled trial[J] . Gregory G Schwartz,Michael A Bolognese,Benoit P Tremblay,Richard Caplan,Howard Hutchinson,Ali Raza,Michael Cressman.American Heart Journal . 2004 (1)

[18]

Comparison of the efficacy and safety of rosuvastatin versus atorvastatin , simvastatin , and pravastatin across doses (STELLAR * * STELLAR = Statin Therapies for Elevated Lipid Levels compared Across doses to Rosuvastatin. Trial)[J] . Peter H Jones,Michael H Davidson,Evan A Stein,Harold E Bays,James M McKenney,Elinor Miller,Valerie A Cain,James W Blasetto.The American Journal of Cardiology . 2003 (2)

← 1 2 →